<!DOCTYPE html>
<html lang="en">
  <head>
            
   

<meta charset="UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<meta http-equiv="X-UA-Compatible" content="ie=edge" />

<link rel="shortcut icon" href="/wiki/assets/favicon.ico" type="image/x-icon" />

<title>Parkinsons • Kang Rui Xiang's Notes</title>

<meta name="description" content="This is my wiki page" />

<meta property="og:title" content="Parkinsons • Kang Rui Xiang's Notes" />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://kangruixiang.github.io/wiki//notes/parkinsons/" />
<meta property="og:image" content="/assets/avatar.png" />
<meta property="og:description" content="This is my wiki page" />

<link rel="canonical" href="https://kangruixiang.github.io/wiki//notes/parkinsons/" />

<link rel="stylesheet" href="/wiki/style.css" />

<style>
  @font-face {
    font-family: "Concourse";
    src: url("/wiki/assets/fonts/concourse_3_regular.woff2") format("woff2");
    font-style: normal;
  }
  @font-face {
    font-family: "Equity";
    src: url("/wiki/assets/fonts/equity_a_regular.woff2") format("woff2");
    font-style: normal;
  }
</style>

  </head>
  <body class="h-screen bg-ember scroll-smooth">
    <div
      class="fixed top-0 w-screen"
    >
    <div class="flex items-center justify-between max-w-4xl px-4 py-4 mx-auto md:px-10 bg-ember bg-opacity-90">
     <a href="/wiki/"> <svg xmlns="http://www.w3.org/2000/svg" class="w-8 h-8" viewBox="0 0 20 20" fill="currentColor">
  <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z" />
</svg></a>

      <nav class="flex space-x-2 font-semibold uppercase">
        <a href="/wiki/" class="p-4 rounded hover:bg-zinc-800 hover:text-zinc-200"
          >Home</a
        >
        <a
          href="/wiki/notes/Step 1"
          class="p-4 font-semibold rounded hover:bg-zinc-800 hover:text-zinc-200"
          >Step 1</a
          >
      </nav>
    </div>
    </div>

    <div class="flex items-center justify-center flex-none max-w-4xl px-6 mx-auto mt-32 mb-32">
      <div  class="font-serif prose prose-lg prose-h1:text-xl prose-h2:text-lg md:prose-2xl md:prose-h1:text-4xl md:prose-h2:text-3xl prose-hr:border-zinc-900 hover:prose-a:bg-zinc-800 hover:prose-a:text-zinc-200"><h1 id="parkinsons" tabindex="-1">parkinsons</h1>
<p>Most <strong>medications for Parkinson disease increase dopamine activity</strong>, either through direct receptor stimulation (eg, <strong>dopamine agonists, carbidopa/levodopa</strong>), decreased dopamine breakdown (eg, <strong>monoamine oxidase [MAO-B] inhibitors</strong>), or increased dopamine release (eg, <strong>amantadine</strong>).  Other medications include <strong>anticholinergics</strong> (which can decrease acetylcholine effect in relation to dopamine effect) and catechol-O-methyl transferase <strong>(COMT) inhibitors</strong>, which can prolong levodopa's effect.  Any medication that increases dopamine activity can cause <strong>psychotic symptoms</strong>.  This patient has developed paranoid delusions and visual hallucinations following an increase in levodopa.  Although dosage reduction or discontinuation of carbidopa/levodopa is an option <strong>(Choice D)</strong>, this would not be the appropriate first step as this medication has significantly improved the patient's motor symptoms and quality of life.  To maintain therapeutic effect, the least potent medications should be reduced or discontinued first, in the following order:  anticholinergics, amantadine, MAO-B inhibitors, COMT inhibitors, dopamine agonists, and, finally, carbidopa/levodopa.  The first step would be to reduce or taper off amantadine while maintaining the dosage of carbidopa/levodopa.</p>
<p>Addition of low-dosage antipsychotics is indicated for medication-induced psychosis that persists despite adjustments to determine the minimum effective dosage of anti-parkinsonian medication.  The low-potency second-generation antipsychotics <strong>quetiapine (Choice A)</strong> and <strong>clozapine</strong> have the lowest incidence of drug-induced parkinsonism and may be indicated.  In contrast, potent D2 dopamine receptor antagonists such as first-generation antipsychotics and the second-generation antipsychotic risperidone <strong>(Choice B)</strong> should be avoided due to the risk of motor symptoms.  Recently, <strong>pimavanserin</strong>, a serotonin 5HT-2A receptor inverse agonist, has been approved by the FDA for the treatment of psychotic symptoms in patients with Parkinson disease.</p>

      </div>
    </div>
    
     <div class="fixed hidden ml-8 right-[5%] 2xl:block top-48 border-l-2 border-zinc-600 px-2"> 
        
      </div>


    <div class="max-w-4xl p-2 mx-auto font-sans font-semibold uppercase bg-emberdark">Backlinks</div>
    <div class="mx-auto font-serif prose prose-lg hover:prose-a:bg-zinc-800 hover:prose-a:text-zinc-200">
      
      <!-- <hr /> -->



<ul>
  
  <li>
    <div class="">
      <a href="/wiki//notes/Psychiatry/" class="peer">Psychiatry</a>
      <div
        role="none"
        class="absolute hidden px-8 py-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-ember prose-headings:hidden prose-hr:hidden"
      >
        <h1 id="psychiatry" tabindex="-1">Psychiatry</h1>
<ul>
<li>Keywords:: <a href="/wiki/notes/Step%203/">Step 3</a>, <a href="/wiki/notes/Medicine/">Medicine</a></li>
</ul>
<hr>
<ul>
<li><a href="/wiki/notes/schizophrenia/">schizophrenia</a></li>
<li><a href="/wiki/notes/catatonia/">catatonia</a></li>
<li><a href="/wiki/notes/PTSD/">PTSD</a></li>
<li><a href="/wiki/notes/adjustment%20disorder/">adjustment disorder</a></li>
<li><a href="/wiki/notes/parkinsons/">parkinsons</a></li>
<li><a href="/wiki/notes/palliative%20care/">palliative care</a></li>
<li><a href="/wiki/notes/second%20generation%20antipsychotics%20do%20not%20treat%20negative%20symptoms/">second generation antipsychotics do not treat negative symptoms</a></li>
<li><a href="/wiki/notes/anorexia%20and%20bulimia%20nervosa/">anorexia and bulimia nervosa</a></li>
<li><a href="/wiki/notes/methamphetammine%20use/">methamphetammine use</a></li>
<li><a href="/wiki/notes/drug%20intoxications/">drug intoxications</a></li>
<li><a href="/wiki/notes/do%20not%20start%20antidepressant%20monotherapy%20in%20bipolar/">do not start antidepressant monotherapy in bipolar</a></li>
<li><a href="/wiki/notes/SPIKES/">SPIKES</a></li>
<li><a href="/wiki/notes/depression%20and%20anxiety%2012%202020%20notes/">depression and anxiety 12 2020 notes</a></li>
<li><a href="/wiki/notes/narcolepsy/">narcolepsy</a></li>
<li>[[treat end of life d</li>
</ul>

      </div>
    </div>
  </li>
  
</ul>


</div>

    <footer>
      <div class="max-w-6xl mx-auto mb-10 text-sm text-center mt-96">
        By Kang Rui Xiang
      </div>
      </div>
    </footer>
  </body>
</html>
